We are live on ! Find out more
TENX icon

Tenax Therapeutics
TENX

26 hedge funds and large institutions have $12.9M invested in Tenax Therapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

13% more funds holding

Funds holding: 23 → 26 (+3)

3.26% more ownership

Funds ownership: 50.54% → 53.8% (+3.3%)

1% less capital invested

Capital invested by funds: $13.1M → $12.9M (-$184K)

Holders
26
Holders Change
+3
Holders Change %
+13.04%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.2M
2
ACM
ADAR1 Capital Management
Texas
+$502K
3
Morgan Stanley
Morgan Stanley
New York
+$329K
4
Raymond James Financial
Raymond James Financial
Florida
+$8.69K
5
TRCT
Tower Research Capital (TRC)
New York
+$6.11K

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$634K
2
Citadel Advisors
Citadel Advisors
Florida
-$74K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$19.1K
4
UBS Group
UBS Group
Switzerland
-$16.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$2.18M – – –
BI
2
BVF Inc
California
$1.98M – – –
Millennium Management
3
Millennium Management
New York
$1.36M +$1.2M +207,088 +778%
VC
4
Vivo Capital
California
$1.2M – – –
Morgan Stanley
5
Morgan Stanley
New York
$1.03M +$329K +56,916 +47%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$978K – – –
IHAM
7
Integral Health Asset Management
New York
$962K – – –
ACM
8
ADAR1 Capital Management
Texas
$896K +$502K +86,816 +126%
VA
9
VR Adviser
New York
$568K -$634K -109,769 -53%
Adage Capital Partners
10
Adage Capital Partners
Massachusetts
$480K – – –
VCIM
11
Velan Capital Investment Management
Georgia
$480K – – –
VPC
12
Vestal Point Capital
New York
$308K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$200K +$5.17K +895 +3%
Vanguard Group
14
Vanguard Group
Pennsylvania
$130K – – –
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$93K -$19.1K -3,313 -17%
Citadel Advisors
16
Citadel Advisors
Florida
$60.4K -$74K -12,796 -55%
Raymond James Financial
17
Raymond James Financial
Florida
$8.66K +$8.69K +1,503 New
TRCT
18
Tower Research Capital (TRC)
New York
$7.19K +$6.11K +1,057 +551%
BlackRock
19
BlackRock
New York
$1.73K – – –
Bank of America
20
Bank of America
North Carolina
$1.43K +$116 +20 +9%
UBS Group
21
UBS Group
Switzerland
$81 -$16.6K -2,879 -100%
Barclays
22
Barclays
United Kingdom
$63 +$64 +11 New
AF
23
Allworth Financial
California
$6 – – –
PWA
24
Physician Wealth Advisors
Utah
$6 – – –
Jones Financial Companies
25
Jones Financial Companies
Missouri
$6 +$6 +1 New
1
2

TENX Hedge Fund Activity: Q2 2025 in Review

26 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q2 2025, worth a combined $12.9M — down 1.4% from $13.1M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new TENX positions and 0 closed out — a net gain of 3 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.2M. The largest seller was VR Adviser, cutting an estimated $634K.

  • 26 institutional investors held Tenax Therapeutics (TENX) as of Q2 2025, up from 23 in Q1 2025.
  • Funds reported $12.9M of Tenax Therapeutics stock for Q2 2025, down 1.4% quarter-over-quarter.
  • 3 funds opened new Tenax Therapeutics positions in Q2 2025 and 0 closed out, a net change of +3 holders.
  • The largest Tenax Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $1.2M added.
  • The largest Tenax Therapeutics seller in Q2 2025 was VR Adviser, an estimated $634K sold.

Based on aggregated 13F filings for Q2 2025.